Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lymphoid Interstitial Pneumonia 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 5Platinum 4Cetuximab 41,2-diaminocyclohexaneplatinum II citrate 4Carboplatin 3Radiotherapy, Intensity-Modulated 2Nivolumab 2Immunoglobulin G 2Gemcitabine 2Gefitinib 2Fluorouracil 2Docetaxel 2Disulfides 2Biopsy 2Bevacizumab 2vandetanib 1temsirolimus 1linrodostat 1ficlatuzumab 1durvalumab 1dl1520 1dehydroftorafur 1cediranib 1atezolizumab 1adavosertib 1X-Rays 1Trioxsalen 1Specimen Handling 1Soybean Proteins 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoid Interstitial Pneumonia × cediranib × Head & Neck × Clear all
NCT00458978 2015-05-05

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡